Watch Out For Tuesday - Will Myovant's HERO Prove Its Mettle?

Myovant Sciences Ltd. (MYOV) is slated to present results from its phase III study of once-daily, oral Relugolix in men with advanced prostate cancer on Tuesday, November 19, 2019.

from RTT - Biotech https://ift.tt/2r1jYll
via IFTTT